Perioperative Chemoradiotherapy May Improve Survival in Urethral Carcinoma
the Cancer Therapy Advisor take:
Patients who received neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy for cT3 and/or cN+ primary urethral carcinoma (PUC) appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without adjuvant chemotherapy, a recent study published online in the journal Annals of Oncology has shown.
For the study, researchers sought to assess the effect of perioperative chemo(radio)therapy) in patients with advanced PUC. Researchers identified 124 patients who were diagnosed and underwent surgery for PUC between 1993 and 2012.
Results showed that the objective response rate was 25% and 33% for neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy, respectively.
For patients who achieved an objective response to neoadjuvant treatment, the 3-year overall survival was 100% for those who received neoadjuvant chemotherapy and 58.3% for those who received neoadjuvant chemoradiotherapy (P = 0.30).
In the locally advanced subset of patients, the 3-year overall survival was 100% for those who received neodjuvant chemotherapy, 100% for those who received neoadjuvant chemotherapy, 50% for those who underwent surgery alone, and 20% for those who underwent surgery plus adjuvant chemotherapy (P = 0.016).
The study demonstrated a significant association between neoadjuvant treatment and improved 3-year relapse-free survival (P = 0.022) and overall survival (P = 0.022).
Patients who received neoadjuvant chemotherapy for primary urethral carcinoma appeared to demonstrate improved survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed